Spruce Biosciences Company Description
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for neurological disorders.
The company is engaged in developing tildacerfont, a non-steroidal therapy designed to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH).
This therapy is currently in Phase 2b clinical trials to evaluate glucocorticoid reduction in adult patients with classic CAH.
Additionally, the company is developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children, which is in Phase 2 clinical trials.
Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses, as well as a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan.
Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Javier Szwarcberg |
Contact Details
Address: 611 Gateway Boulevard South San Francisco, Delaware 94080 United States | |
| Phone | 415 655 4168 |
| Website | sprucebio.com |
Stock Details
| Ticker Symbol | SPRB |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US85209E1091 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Javier Szwarcberg M.D., M.P.H. | Chief Executive Officer and Director |
| Michael G. Grey | Executive Chairman |
| Dr. Kirk Ways M.D., Ph.D. | Chief Medical Officer and Director |
| P. J. Ramtin | Senior Vice President of Business Operations |
| Heidi Petersen M.P.H. | Senior Vice President of Regulatory and Quality |